Given that hyper-activation of IGFIR has been observed in NSCLC patient specimens [29] and disruption of IGFIR signaling with monoclonal antibodies or small molecules inhibits tumor growth in vivo [30,31], a better understanding of the molecular features of this model is warranted. The gene discussed is IGF1R; the disease is non-small cell lung carcinoma.